Sernova Corp. (TSE:SVA – Get Free Report) shares were down 18.5% on Monday . The stock traded as low as C$0.11 and last traded at C$0.11. 674,159 shares were traded during mid-day trading, an increase of 415% from the average session volume of 130,839 shares. The stock had previously closed at C$0.14.
Sernova Stock Performance
The company has a current ratio of 0.03, a quick ratio of 18.11 and a debt-to-equity ratio of -21.98. The stock’s 50 day moving average price is C$0.12 and its 200 day moving average price is C$0.14. The company has a market capitalization of C$43.43 million, a price-to-earnings ratio of -2.88 and a beta of -0.43.
Sernova (TSE:SVA – Get Free Report) last issued its earnings results on Thursday, September 10th. The company reported C($0.01) earnings per share for the quarter. Analysts expect that Sernova Corp. will post -0.08 earnings per share for the current year.
About Sernova
Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.
Recommended Stories
- Five stocks we like better than Sernova
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
- Rocket Lab Insiders Are Selling—But Institutions Keep Buying
Receive News & Ratings for Sernova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sernova and related companies with MarketBeat.com's FREE daily email newsletter.
